NVS019: Real-world evaluation of amblyopic patient characteristics, clinical outcomes, and treatment patterns using the IRIS Registry

Research Lead:

Euna B. Koo, M.D. 1 ; Lauren A. Wiener, M.S. 2 ; Annie Syntosi,

Purpose

To characterize the demographics, eye-related comorbidities, clinical characteristics, clinical outcomes, type of amblyopia tests used, and treatment patterns of a large cohort of pediatric, teenage, and adult amblyopic patients from the IRIS (Intelligent Research in Sight) Registry.

Methods

In this retrospective electronic health record analysis, we analyzed 456,818 patients, of whom 197,583 (43.3%) were pediatric patients; 65,308 (14.3%), teenagers; and 193,927 (42.5%), adults. Baseline best-corrected visual acuity examination in both eyes was conducted within 90 days prior to index date. Three age cohorts were analyzed based on age at the index date: pediatric (3-12 years), teen (13-17 years), and adult (18-50 years).

Results

At index date, unilateral amblyopia was more common than bilateral amblyopia in all age cohorts (pediatric, 55% vs 45%; teen, 61% vs 39%; adult, 63% vs 37%). In unilateral amblyopic patients, severe amblyopia was more frequent in adults (21%) than in pediatric patients (12%) and teenagers (13%); in bilateral amblyopic patients, severity was comparable in pediatric patients and adults (4% severe in both). The greatest level of visual acuity improvement was demonstrated in pediatric patients with severe unilateral amblyopia at baseline. Pediatric patients showed significant improvement in stereopsis over time at years 1 (P = 0.000033) and 2 (P = 0.000039) at the population level (per χ2 test vs baseline).

Conclusions

Our findings highlight the need for more efficacious amblyopia therapies in older, more severe patients with refractory disease.

Real-World Clinical and Anatomical Outcomes in Patients with Diabetic Macular Edema Treated with Faricimab: The FARETINA-DME Study

May 9, 2024
Read More

IRIS® Registry Analysis of Anti-VEGF Treatment in Patients With Coexisting Neovascular Age-Related Macular Degeneration and Geographic Atrophy

May 9, 2024
Read More

A Natural Language Processing Approach to Identify Patients with Uveitic Macular Edema in the IRIS®️ Registry

May 6, 2024
Read More

Automated Segmentation of Geographic Atrophy Using Machine Learning on Real-World Fundus Autofluorescence Ophthalmic Images in the IRIS®️ Registry

May 6, 2024
Read More

Real-World Clinical and Anatomical Outcomes in Patients With Neovascular Age-Related Macular Degeneration Treated With Faricimab: The FARETINA-AMD Study

May 6, 2024
Read More

Leveraging real-world data from the American Academy of Ophthalmology’s IRIS®️ Registry to evaluate the use and impact of approved medical devices and software algorithms in support of FDA strategic priorities

April 10, 2024
Read More

Ab Interno Minimally Invasive Glaucoma Surgery Combined with Cataract Surgery and Cataract Surgery Alone: IRIS®️ Registry Study

April 7, 2024
Read More

Comparison of Methods of Clinical Trial Emulation Utilizing Data from the Comparison of AMD Treatment Trial (CATT) and the IRISⓇ Registry

April 3, 2024
Read More

Multi-registry analysis of patients with multiple sclerosis and neuromyelitis optica to improve capture of demographic data and compare visual outcomes

February 11, 2024
Read More

Vitreoretinal Specialist Use of Ancillary Testing: An IRIS®️ Registry Analysis

October 20, 2023
Read More
Qdata

Talk to a Qdata Expert

Take a minute to submit your contact information and one of our team members will reach out to you.